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Conclusions 
 Investigate MAS1-86 impact on the apicoplast’s metabolic pathways and apicoplast biogenesis in 
greater detail.
 Test cross – resistance in  MAS1-86 selected synchronized ring stage cultures to ART since ring 
stages exhibit ART resistance. 
 Test cross-resistance in WLL-resistant mutants to MAS1-86 to investigate MAS1-86 inhibition of 
the proteasome.
 Investigate UPR after treatment of MAS1-86.
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 Analogs of MAS1-86 were then tested against 
P. falciparum. MAS1-86 was identified                                                                          
as most potent  inhibitor.
Background
Figure 5.  MAS1-86 selected parasites display 6X to 23X increase in resistance to MAS1-86. (A) MAS1-86 growth 
inhibition assays tested against various asynchronous parasites as indicated, and the (B) corresponding IC50 +/- SEM 
values. Parasitemia was assessed 72 hours after compound addition. Parasite DNA was stained with SYBR Green I and 
respirating mitochondria stained by MitoTracker Deep Red, then assessed by flow cytometry. Statistical significance 
ssessed using Student’s t-test with Welch’s correction. *p < 0.05; **p <0.01. n = 3.
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Figure 4. MAS1-86 stepwise resistance selections. Two replicates, Flask 1 and Flask 2, of Cam3.II K13C580Y parasites 
were exposed to MAS1-86 in increasing concentrations, as indicated on the right axis. Parasitemia over time is tracked, 
as indicated on the left axis. Green dots correspond to profiled parasites in Figure 2.
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Figure 7. Morphology of parasites exposed to MAS1-86 across the asexual blood stages. (A) Ring stage, (B) trophozoite
stage, and (C) schizont stage Cam3.II K13 C580Y parasites were treated with DMSO, 250 nM, or 500 nM MAS1-86 for the 
hours indicated above. Thin blood smears were made, stained with Giemsa, and imaged by light microscopy using a 
100X objective.
Figure 8. K13 haplotype does not influence parasite 
susceptibility to MAS1-86. Asynchronous K13 mutants were 
exposed to MAS1-86 for 72 hours, and the dose responses are 
plotted. n=3.
Figure 9. MAS1-86-resistant parasites do not show cross-
resistance to WLL. Dose response curves of indicated parasites 
exposed to WLL for 72 hours. n=3
Figure 6. IPP does not rescue MAS1-86 parasite inhibition. (A) 72-hour growth inhibition assays of MAS1-86 in the 
absence or presence of IPP tested against Cam3.II K13 C580Y. (B) MAS1-86 IC50 values assayed at 72 hours and 120 hours. 
A 10-fold reduction in IC50 values at 120 hours compared to72 hours indicates a delayed death phenotype. 
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 In 2019, ~229 million malaria cases reported globally, causing 409,000 deaths 1.
 Malaria is caused by the Plasmodium parasite with cyclical infection in human and 
Anopheles mosquito host. P. falciparum is the most prevalent species 1 .
 Blood stage parasites cause malaria symptoms. The lifecycle                                                                  
begins with merozoites that invade red blood cells. They develop 
into ring stages (0-23 hours post invasion, hpi), trophozoite stages 
(24-39 hpi), and maturing into schizont stages (40-48 hpi) 2.
 Artemisinin-based combination therapy (ACT) is the first-line 
treatment for uncomplicated falciparum malaria 3.
 Resistance to all artemisinin (ART) is a widespread problem 3.
 Point mutations in Kelch 13 confer ART resistance. The C580Y mutation is the most 
abundant in SE Asia. The R539T mutation displays high levels of resistance in vitro.
 P. falciparum’s apicoplast, an essential organelle that generates fatty acids, heme, 
and isoprenoid precursors, is a promising drug target since humans lack this 
organelle 4.
 The apicoplast’s primary function in asexual 
life stages is to produce isoprenoid precursor 
isopentenyl pyrophosphate (IPP) via the 
methylerythritol phosphate (MEP) pathway. 
IPP supplementation has shown to chemically 
rescue MEP inhibited cultures 5,6.
 Delayed death phenotype is when growth of treated parasite is 
unaffected, but growth arrest is observed in the progeny. This 
is seen when apicoplast biosynthesis and metabolic pathways 
are inhibited 6.
 The apicoplast-located PfClpC/P complex degrades proteins and has chymotrypsin-
like proteolytic activity 4. PfClpC is a chaperone to the PfClpP protease 4.
 Aberrant schizont morphology with fewer nuclei in auto-inhibited inhibited PfClpC has been 
reported 7.
 P. falciparum 26S proteasome is a cytoplasmic protease. The β1, β2, and β5 subunits 
have caspase-like, trypsin-like and chymotrypsin-like activity, respectively 4. WLL 
inhibits the β2 and β5 subunits 4.
 The unfolded protein response (UPR) upregulates proteasome activity 4.
 PfClpC has 27% identity to the Staphylococcus aureus homolog ClpX. MAS1-86 inhibited 
multi-drug resistant S. aureus 8.
Conclusions
 MAS1-86 selected parasites display 6-23 - fold increased resistance to MAS1-86.
 MAS1-86 does not target the MEP pathway, since IPP fails to rescue MAS1-86 inhibition.
 MAS1-86 inhibition caused a delayed progression in late trophozoite through schizont stages, 
with fewer nuclei observed in schizonts.
 MAS1-86 kills artemisinin-sensitive and artemisinin-resistant parasites. 
 MAS1-86 resistant parasites do not show cross resistance to proteasome β2 and β5 subunit 
inhibitor, WLL, which has the same chymotrypsin-like activity as ClpP. References
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Figure 1. P. falciparum asexual 
lifecycle. Credit to 2 for figure
Figure 2. Synthesis of MEP pathway and isoprenoid products in P. falciparum. 
Adapted from 5
Figure 3. MAS1-86 and analogs tested against P. falciparum. MAS1-86 
circled in red.
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